The Pathogen Genomics Diagnostics Market is projected to register a strong CAGR during the forecast period (2026-2031).
The Pathogen Genomics Diagnostics Market is expanding rapidly as genomic technologies enable precise identification and characterisation of infectious agents. These diagnostics support outbreak tracking, antimicrobial resistance detection, and personalized treatment. Increasing adoption of sequencing technologies and global focus on infectious disease surveillance are driving strong market growth.
The overview of this fledgling pathogen genomics diagnostics market demonstrates the application of advanced sequencing technologies for pathogen genome characterisation (e.g. viruses) to enable fast, accurate, and reliable pathogen identification/discrimination in a clinical laboratory. The global genomics diagnostics market is growing rapidly (CAGR of 23%) (i.e. ‘high-growth’), driven by increasing demand for more accurate, fast, and precise identification of pathogen mutants, epidemiology, and drug resistance identification through next generation sequencing and polymerase chain reaction (PCR). Genomics diagnostics are also playing a key role in supporting community health by improving public health organisations' capacity to conduct genomic surveillance, investigate outbreaks, or utilise precision medicine. The market for Genomic Diagnostics is being bolstered by increased funding for genomics infrastructure, combined with the integration of Bioinformatics and Artificial Intelligence to enhance global diagnostic capabilities and support disease containment through surveillance.
Increasing Incidence of Infectious Diseases: The demand for rapid and accurate pathogen detection technologies is increasing due to the growing global burden of disease from infectious pathogens.
Advancements in Sequencing Technologies: The rapid developments in NGS and portable NGS technologies are improving the speed, accuracy, and accessibility of diagnostics.
Government and Public Health Initiatives: Government and public health initiatives are supporting the increased use of genome sequencing for the purpose of surveillance and pandemic preparedness.
Demand for Personalized and Precision Medicine: Due to the availability of genomic data, personalized and precision medicine is being adopted more widely in practice.
Some challenges facing the market are the high cost of sequencing technologies; the complexity of data analysis; and the requirement of skilled personnel to analyze large amounts of data. Infrastructure for the adoption of pathogen genomics in LMICs is also limited. However, new opportunities exist for portable sequencing devices, artificial intelligence-based analytics, and new applications for controlling outbreaks and precision medicine. The increasing global effort to monitor antimicrobial resistance and real-time disease surveillance are also expected to contribute to the continued growth of the pathogen genomics market.
November 2025: Thermo Fisher Scientific announced that its EXENT Analyser and Immunoglobulin Isotypes (GAM) Assay received 510(k) clearance from the U.S. Food and Drug Administration as an automated molecular diagnostic platform designed to assist in the detection and identification of multiple myeloma and related plasma cell disorders. The system offers enhanced sensitivity for measuring M-proteins at low concentrations and automates workflows to provide clear, reliable results that support early and confident clinical diagnoses. This clearance strengthens Thermo Fisher’s position in advanced molecular diagnostics and exemplifies how machine learning and automated analysis tools are being integrated into clinical laboratories to support oncologic testing and disease monitoring.
The market is segmented by product type, technology, application and geography.
Kits and reagents comprise an important category within the pathogen genomics market because they are necessary for preparing samples, amplifying samples, and sequencing samples. Kits and reagents include library preparation kits; extraction reagents; and sequencing consumables such as reagents, sample plates, and consumables. Since laboratories and research institutions will utilize these products on a continual basis, they will continue to support steady demand for these products. Successful completion of infection studies with improvements in the availability of ready-to-use kits and automated kits will make work more efficient, reduce the turnaround time for results, and encourage the use of sequencing-based diagnostics and develop additional genomic surveillance programs. As a result, demand for high-quality and dependable reagents will increase in the pathogen genomics market.
The next-generation sequencing (NGS) technology dominates the genomic pathogen surveillance and outbreak tracking system. The NGS allows high-quality detection of mutation and strain variation as well as resistant genes present in pathogens. NGS will be the primary method used for pathogen genomic analysis in 2025 and will serve as a vital resource for public health organisations that rely on multiple sample analyses simultaneously. With continued advancements in sequencing technology, lower cost of sequencing, and development of data analysis tools, the NGS will continue to solidify its position as the leading tool for diagnostics in pathogen genomics.
The infectious disease diagnosis segment is the leading application for pathogen genomics. While the pathogen genomics’ precise identification of infectious agents. Infectious disease diagnostic testing generates large quantities of genetic data to provide clinically applicable data about the pathogen, and allows for targeted treatment options to improve patient outcomes. In 2025, genomic diagnostics will increasingly be integrated into clinical workflows to diagnose complex and emerging infective diseases. For example, the ability to identify co-infecting pathogens and rare pathogens improves the accuracy of disease diagnostic testing. Increasing global incidence of infectious disease and the growing demand for personalisation of treatment approaches are driving adoption of pathogen genomics for clinical diagnostics.
North America is the largest geographic region for diagnostics related to pathogens due to its advanced sequencing technology and high levels of investment in scientific research and public health initiatives. The high rates of next-generation sequencing use and the incorporation of artificial intelligence into diagnostic testing facilitate the rapid identification of pathogens. Concurrently, public health initiatives focused on genomic surveillance and monitoring of antimicrobial resistance continue to drive the growth of infectious disease diagnostics within North America.
South America is experiencing gradual growth as countries invest in improving healthcare infrastructure and genomic capabilities. Increasing focus on infectious disease surveillance and outbreak management is supporting adoption. However, limited access to advanced sequencing technologies and budget constraints may restrict rapid expansion. Continued investments are expected to enhance market growth in the coming years.
The growth trend in Europe will continue, driven by an increase in the general population's awareness of genomic surveillance programs. and the establishment of strong regulatory frameworks. Collaboration between research institutions and healthcare providers is enhancing diagnostic capabilities and supporting the adoption of pathogen genomics in clinical and public health settings.
The Middle East & Africa region is witnessing emerging growth supported by increasing investments in healthcare and public health initiatives. Governments and international organisations are focusing on strengthening genomic surveillance systems. Although adoption is still developing, rising awareness of infectious disease monitoring and improving infrastructure are expected to drive steady growth in pathogen genomics diagnostics.
Asia-Pacific is the fastest-growing region due to increasing investments in genomics infrastructure and rising infectious disease burden. Countries such as China, India, and Japan are expanding sequencing capabilities to strengthen disease surveillance. Growing awareness of precision diagnostics and government initiatives supporting healthcare modernization are driving adoption of pathogen genomics diagnostics across the region.
· Illumina
· Thermo Fisher Scientific
· Roche Diagnostics
· QIAGEN
· Agilent Technologies
· Bio-Rad Laboratories
· Danaher Corporation
· BGI Genomics
· Oxford Nanopore Technologies
· Pacific Biosciences
Roche Diagnostics is a globally recognized leader in molecular diagnostic products, tools, and technologies. Within its product offerings you will find real-time PCR systems, high-throughput testing solutions, and companion diagnostics used for oncological, infectious diseases, and genetic testing. Its diagnostic technology facilitates laboratory automation and collaboration through integration with laboratory information systems, allowing for optimal workflows and data management. Roche also manufactures multiplex assays to enable the simultaneous detection of various pathogens. Furthermore, Roche's continuous investments in new technologies including next-generation sequencing and biomarker discovery are helping to solidify its role in the field of precision medicine. The breadth of Roche's portfolio and its global reach establish it as one of the leading diagnostic companies, helping to make it an essential component of clinical and reference labs.
Thermo Fisher Scientific is a manufacturer and distributor of many types of molecular diagnostic technologies, including PCR technology, next-generation sequencing technology, reagents, and bioinformatics software. Additionally, Thermo Fisher's platforms provide high-throughput workflows, allowing labs to increase their testing capacity. Thermo Fisher also offers package solutions for integrated service/support to help labs achieve optimal assay performance and compliance. Thermo Fisher is well-known for its strong commitment to research and development in order to support ongoing innovation in molecular testing and laboratory automation, positioning it to be a critical partner for clinical and research labs globally.
| Report Metric | Details |
|---|---|
| Forecast Unit | Billion |
| Growth Rate | Ask for a sample |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Product Type, Technology, Application, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|